PFE · 10-Q · 2026Q2 · Full report

Liquidity and Debt Position

PFIZER INC · 2026-08-04 · Importance 59 · Surprise 48 · No source text

Pfizer reported financing cash outflows of $6.519 billion in the first six months of 2026, compared with $8.423 billion in the 2025 period. Net repayments of short-term borrowings decreased by $3.0 billion, while repayments of long-term debt decreased by $2.5 billion; the comparison was partly offset by the absence of a $3.7 billion long-term debt issuance in 2025. Pfizer had access to a $7.0 billion committed revolving credit facility maturing in October 2030, plus $226 million of additional lines of credit, essentially all unused at filing.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
cashpositiverealized+0.9%Six months cash provided by/(used in) financing activities for the six months ended June 28, 2026: $(6,519) million compared with $(8,423)…
cashpositiverealized+0.9%The change in financing activities was driven mainly by a $3.0 billion decrease in net repayments of short-term borrowings and a $2.5…